"Potassium Channel Blockers/adverse effects"[MAJR] - Search Results

Year	Number of Results
2001	3
2002	7
2003	6
2004	5
2005	6
2006	5
2007	10
2008	15
2009	12
2010	11
2011	15
2012	13
2013	9
2014	6
2015	16
2016	12
2017	10
2018	6
2019	8
2020	2
2021	7
2024	0

1

Flavonoids and hERG channels: Friends or foes?

Saponara S, Fusi F, Iovinelli D, Ahmed A, Trezza A, Spiga O, Sgaragli G, Valoti M. Saponara S, et al. Eur J Pharmacol. 2021 May 15;899:174030. doi: 10.1016/j.ejphar.2021.174030. Epub 2021 Mar 13. Eur J Pharmacol. 2021. PMID: 33727059 Review.

2

Development of Safe Drugs: The hERG Challenge.

Kalyaanamoorthy S, Barakat KH. Kalyaanamoorthy S, et al. Med Res Rev. 2018 Mar;38(2):525-555. doi: 10.1002/med.21445. Epub 2017 May 3. Med Res Rev. 2018. PMID: 28467598 Review.

3

Effects of common antitussive drugs on the hERG potassium channel current.

Deisemann H, Ahrens N, Schlobohm I, Kirchhoff C, Netzer R, Möller C. Deisemann H, et al. J Cardiovasc Pharmacol. 2008 Dec;52(6):494-9. doi: 10.1097/FJC.0b013e31818eec8d. J Cardiovasc Pharmacol. 2008. PMID: 19034038

4

Recent developments in computational prediction of HERG blockage.

Wang S, Li Y, Xu L, Li D, Hou T. Wang S, et al. Curr Top Med Chem. 2013;13(11):1317-26. doi: 10.2174/15680266113139990036. Curr Top Med Chem. 2013. PMID: 23675938 Review.

5

Immunomodulatory and protective effects of interleukin-4 on the neuropathological alterations induced by a potassium channel blocker.

Ahras-Sifi N, Laraba-Djebari F. Ahras-Sifi N, et al. J Neuroimmunol. 2021 Jun 15;355:577549. doi: 10.1016/j.jneuroim.2021.577549. Epub 2021 Mar 17. J Neuroimmunol. 2021. PMID: 33839521

6

Toxicology of potassium channel-directed compounds in mosquitoes.

Larson NR, Carlier PR, Gross AD, Islam RM, Ma M, Sun B, Totrov MM, Yadav R, Bloomquist JR. Larson NR, et al. Neurotoxicology. 2017 May;60:214-223. doi: 10.1016/j.neuro.2016.05.021. Epub 2016 Jun 1. Neurotoxicology. 2017. PMID: 27262624

7

Targeting potassium channels: new advances in cardiovascular therapy.

Martínez-Mármol R, Roura-Ferrer M, Felipe A. Martínez-Mármol R, et al. Recent Pat Cardiovasc Drug Discov. 2008 Jun;3(2):105-18. doi: 10.2174/157489008784705386. Recent Pat Cardiovasc Drug Discov. 2008. PMID: 18537761 Review.

8

Computational investigations of hERG channel blockers: New insights and current predictive models.

Villoutreix BO, Taboureau O. Villoutreix BO, et al. Adv Drug Deliv Rev. 2015 Jun 23;86:72-82. doi: 10.1016/j.addr.2015.03.003. Epub 2015 Mar 12. Adv Drug Deliv Rev. 2015. PMID: 25770776 Review.

9

Clinical overview of the seizure risk of dalfampridine.

Haut SR, Bienen EJ, Miller A. Haut SR, et al. Expert Opin Drug Saf. 2012 Jul;11(4):651-7. doi: 10.1517/14740338.2012.697896. Epub 2012 Jun 18. Expert Opin Drug Saf. 2012. PMID: 22703551 Review.

10

The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.

Thomas D, Karle CA, Kiehn J. Thomas D, et al. Curr Pharm Des. 2006;12(18):2271-83. doi: 10.2174/138161206777585102. Curr Pharm Des. 2006. PMID: 16787254 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

161 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Results by year